History

The Development

The Grünenthal Group founded in 1946 is an independent, family-owned international research based pharmaceutical company headquartered in Aachen, Germany. In 1947 Grünenthal was the first West German company to produce and distribute penicillin. Years later, 1977, Tramal®, the world’s most prescribed pain medication with central effect and only one active ingredient, appeared on the market. Since 1979 the Grünenthal Group has grown to have affiliates in 26 countries worldwide. Grünenthal products are sold in more than 155 countries and approx. 4,500 employees are working for the Grünenthal Group worldwide.

In 2000, Grunenthal opened its US affiliate, Grunenthal USA in New Jersey.  In that same year, Zaldiar®and Transtec® were launched globally. In 2001, Grünenthal developed and introduced the first patch for pain in Europe. Since 2004, Grünenthal has made considerable investments in R&D and late clinical trials. Tapentadol was approved in the US in 2008 and marketed in 2009 with the launch of Nucynta® with Johnson & Johnson.

Building on its unique position in pain, Grünenthal’s objective is to become the most patient-centric company and leader in therapy innovation. Grünenthal is always searching for innovative ways to treat pain better, more sustainably and with fewer side effects. Our research and development strategy concentrates on select fields of therapy and state-of-the-art technologies. We constantly are searching for new ways to treat pain better, more effectively, and with fewer side-effects than before.

In 2011, Grünenthal re-marketed its’ proprietary TRF (Tamper Resistant Formulation) technology under the brand INTAC®. INTAC® is a novel tablet form which restricts manipulation due to its high mechanical stability and poor solubility and thus impedes drug abuse.

2011 Palexia® available in UK, Spain, Italy, Denmark, Sweden, Switzerland and Ireland; FDA approval of Tapentadol ER (August) for chronic pain.
2010 Marketing authorization of Tapentadol IR and PR in 26 EU countries
2009 EU submission of Tapentadol for acute and chronic pain, launch of Nucynta® in the US by Johnson & Johnson
2008 Approval of Tapentadol in the US
Since 2004 Broad investments in R&D and late clinical trials
Since 2000 Global launches (Zaldiar®, Transtec®)
Since 1990 Increasing internationalization of Grünenthal through local founding of subsidiaries and acquisitions
1979 Expansion of the Latin America business through founding of subsidiaries in Columbia and Chile
1977 Tramal® launched – worldwide partnering
1968 First international activities
1947 Registration of Penicillin
1946 Hermann Wirtz founded Chemie Grünenthal GmbH